1
00:00:02,480 --> 00:00:10,080
Speaker 1: Bloomberg Audio Studios, Podcasts, Radio News. This is Bloomberg BusinessWeek

2
00:00:10,400 --> 00:00:14,120
Speaker 1: with Carol Masser and Tim Steneveek on Bloomberg Radio.

3
00:00:14,680 --> 00:00:17,280
Speaker 2: Carol, this story crossing by Rachel Matt's just about one

4
00:00:17,360 --> 00:00:19,919
Speaker 2: pm this afternoon. This is pretty cool. Open ai is

5
00:00:19,960 --> 00:00:22,360
Speaker 2: releasing a free tool. It's aimed at making it easier

6
00:00:22,360 --> 00:00:25,560
Speaker 2: for scientists to use chat GPT to draft research papers

7
00:00:25,840 --> 00:00:28,000
Speaker 2: and collaborate with colleagues. It's part of a larger effort

8
00:00:28,040 --> 00:00:30,720
Speaker 2: to position its chatbot as an aid for scientific work

9
00:00:31,160 --> 00:00:34,600
Speaker 2: and discoveries. Okay, it's called Prism. Open ai is rolling

10
00:00:34,640 --> 00:00:37,360
Speaker 2: it out today. It uses the company's GPT five point

11
00:00:37,400 --> 00:00:39,920
Speaker 2: two AI model to carry out task related to writing

12
00:00:40,280 --> 00:00:43,920
Speaker 2: and revising academic work. A scientist, for example, might ask

13
00:00:43,960 --> 00:00:45,839
Speaker 2: it to help improve the way a paper is written

14
00:00:46,040 --> 00:00:48,000
Speaker 2: and find related papers to cite in their work, or

15
00:00:48,040 --> 00:00:50,720
Speaker 2: generate a computerized version of a handwritten diagram.

16
00:00:51,200 --> 00:00:53,360
Speaker 3: Just be careful not to copy somebody else's work, or

17
00:00:53,479 --> 00:00:59,320
Speaker 3: is gonna say, well, you won't be not good citations

18
00:00:59,360 --> 00:00:59,920
Speaker 3: are important.

19
00:01:00,440 --> 00:01:05,240
Speaker 2: I think the uh administration ran into some issues with

20
00:01:05,720 --> 00:01:11,440
Speaker 2: using AI to come out with some guidelines in recent months,

21
00:01:11,520 --> 00:01:13,840
Speaker 2: and it was found that it's cited papers that don't

22
00:01:13,840 --> 00:01:14,640
Speaker 2: actually exist.

23
00:01:14,800 --> 00:01:17,559
Speaker 3: Yeah, it's it's it's super interesting. I think we're finding

24
00:01:17,560 --> 00:01:19,840
Speaker 3: our way. But I do agree, and I think there's

25
00:01:19,840 --> 00:01:22,840
Speaker 3: a momentum of AI in general. What it couldn't do

26
00:01:22,880 --> 00:01:25,880
Speaker 3: maybe for the healthcare space, for the science space. We

27
00:01:25,959 --> 00:01:27,800
Speaker 3: have a great voice on this. We love touching base

28
00:01:27,840 --> 00:01:31,960
Speaker 3: with her. Jenny Rook, founder and managing director of Genera Ventures.

29
00:01:32,000 --> 00:01:35,640
Speaker 3: It's a VC firm. It invests in, it invests in

30
00:01:36,000 --> 00:01:38,560
Speaker 3: having a tough I'm having a tough time on this Tuesday.

31
00:01:38,800 --> 00:01:40,560
Speaker 3: I blame the snow and maybe being a little off.

32
00:01:41,360 --> 00:01:43,560
Speaker 3: She says, the quote next generation of companies at the

33
00:01:43,560 --> 00:01:47,279
Speaker 3: convergence of technology and biology. This is what she invests in. Jenny,

34
00:01:47,319 --> 00:01:51,160
Speaker 3: good to have you back with us. So talk to

35
00:01:51,240 --> 00:01:55,200
Speaker 3: us about new year, maybe some new ideas, maybe some

36
00:01:55,280 --> 00:01:58,680
Speaker 3: new momentum. Uh. The JP Morgan Healthcare Conference wrapped up

37
00:01:58,680 --> 00:02:01,960
Speaker 3: earlier this month. You were there. Tell us what we

38
00:02:02,040 --> 00:02:04,920
Speaker 3: need to know, especially for those who are listening and

39
00:02:04,960 --> 00:02:08,640
Speaker 3: watching in terms of the investing landscape, trends, narratives in

40
00:02:08,680 --> 00:02:09,240
Speaker 3: this space.

41
00:02:10,680 --> 00:02:12,400
Speaker 4: Sure, I'm happy to good to be back with you,

42
00:02:12,480 --> 00:02:16,760
Speaker 4: Caroly and Tim. Yeah, it was a dynamic year for

43
00:02:16,960 --> 00:02:19,520
Speaker 4: the JP morgan Bytech conference that happens every year here

44
00:02:19,520 --> 00:02:23,760
Speaker 4: in San Francisco. It is always good sort of bell

45
00:02:23,840 --> 00:02:26,839
Speaker 4: weather for how people are feeling going into the new year.

46
00:02:27,720 --> 00:02:29,880
Speaker 4: I would say the headline that I kept hearing in

47
00:02:29,919 --> 00:02:33,720
Speaker 4: conversations around here was cautiously optimistic, which you know, I'll

48
00:02:33,760 --> 00:02:36,799
Speaker 4: take it after the last couple of years, although I

49
00:02:36,919 --> 00:02:39,679
Speaker 4: must admit that was a phrase that we said last

50
00:02:39,760 --> 00:02:43,080
Speaker 4: year as well, and then twenty twenty five happened with

51
00:02:43,120 --> 00:02:47,919
Speaker 4: all its uncertainties, but there was a different, probably different feel.

52
00:02:48,080 --> 00:02:51,239
Speaker 4: There were more people here actually this year than last year.

53
00:02:51,320 --> 00:02:57,120
Speaker 4: Generally speaking, events were quite well attended, and I think

54
00:02:57,120 --> 00:03:00,359
Speaker 4: there was a lot of energy around the very real

55
00:03:00,400 --> 00:03:04,359
Speaker 4: impacts as you were just talking about, of AI on

56
00:03:04,600 --> 00:03:06,920
Speaker 4: health and science, and also some of the shifts in

57
00:03:06,960 --> 00:03:11,400
Speaker 4: the availability of funding, both public and private for advancing

58
00:03:11,400 --> 00:03:14,400
Speaker 4: health care and science, actually along the lines of your

59
00:03:14,440 --> 00:03:19,239
Speaker 4: previous guests. So I would say, in general, lots to

60
00:03:19,400 --> 00:03:22,679
Speaker 4: be excited about, again, perhaps cautiously. Yeah.

61
00:03:22,720 --> 00:03:25,720
Speaker 2: We spoke to you know, just a couple of weeks

62
00:03:25,760 --> 00:03:27,880
Speaker 2: ago from the JPM conference. We heard from some of

63
00:03:27,880 --> 00:03:31,240
Speaker 2: the heads or chairs of the biggest pharmaceutical companies out there.

64
00:03:32,600 --> 00:03:37,560
Speaker 2: Are you also seeing like the early stage stuff. Are

65
00:03:37,600 --> 00:03:40,320
Speaker 2: you seeing a lot of opportunities there still? Because as

66
00:03:40,320 --> 00:03:41,880
Speaker 2: we've spoke to you a lot about quite you know

67
00:03:41,920 --> 00:03:44,720
Speaker 2: over the last year, a lot of that stems from

68
00:03:44,760 --> 00:03:47,920
Speaker 2: academic research. There are questions about funding. We just spoke

69
00:03:47,920 --> 00:03:50,480
Speaker 2: about it with Janet Lauren, you know, in these universities,

70
00:03:50,480 --> 00:03:53,200
Speaker 2: and that funding drying up from the federal government. Is

71
00:03:53,240 --> 00:03:54,360
Speaker 2: that excitement still?

72
00:03:54,400 --> 00:03:54,680
Speaker 1: There?

73
00:03:55,040 --> 00:03:58,240
Speaker 2: Are the opportunities still there? Are you having a hard

74
00:03:58,280 --> 00:04:01,240
Speaker 2: time picking and choosing which investments to make because there

75
00:04:01,240 --> 00:04:02,880
Speaker 2: are a plethora of investments to make.

76
00:04:04,520 --> 00:04:07,040
Speaker 4: I think there are always going to be opportunities because

77
00:04:07,080 --> 00:04:10,280
Speaker 4: there's so much we're still learning about basic science and

78
00:04:10,320 --> 00:04:12,960
Speaker 4: how to use it. And as we've been talking about

79
00:04:13,000 --> 00:04:17,480
Speaker 4: the acceleration of the ability to get some data as

80
00:04:17,680 --> 00:04:20,840
Speaker 4: a scientist, as a researcher, as a technology developer, as

81
00:04:20,839 --> 00:04:26,120
Speaker 4: an entrepreneur, get that data, reincorporate anyone's thinking with the

82
00:04:26,160 --> 00:04:29,600
Speaker 4: tools of AI, and come up with new ways to

83
00:04:29,640 --> 00:04:32,960
Speaker 4: pursue either the business plan or the scientific research that

84
00:04:33,080 --> 00:04:37,479
Speaker 4: Flywheel is spending faster with the assistance of AI and

85
00:04:37,520 --> 00:04:42,600
Speaker 4: other kinds of connectivity and collaboration. So that's definitely happening.

86
00:04:42,760 --> 00:04:44,440
Speaker 4: I think One of the things we've talked about in

87
00:04:44,480 --> 00:04:47,960
Speaker 4: our conversations in the past is while it was very

88
00:04:48,000 --> 00:04:52,960
Speaker 4: much disruptive to people's expectations about where federal dollars were

89
00:04:53,000 --> 00:04:56,839
Speaker 4: going to be coming from for advancing science, we've seen

90
00:04:56,839 --> 00:05:01,920
Speaker 4: a couple of things. One the resilience of those driven,

91
00:05:02,000 --> 00:05:05,120
Speaker 4: passionate researchers who are looking to get their work done

92
00:05:05,279 --> 00:05:08,320
Speaker 4: one day, one way or another figuring out ways to

93
00:05:09,320 --> 00:05:13,640
Speaker 4: get that funding done. As well as entrepreneurs. They tend

94
00:05:13,680 --> 00:05:16,600
Speaker 4: to be the grittiest and the most driven. So we're

95
00:05:16,640 --> 00:05:22,640
Speaker 4: seeing in some cases this actually, perhaps counterintuitively, is creating

96
00:05:23,000 --> 00:05:27,880
Speaker 4: a new category or more opportunities for the early stage investor,

97
00:05:29,279 --> 00:05:32,720
Speaker 4: where perhaps a researcher who hadn't been thinking of commercializing

98
00:05:32,839 --> 00:05:35,720
Speaker 4: their research is starting to think, well, is there an

99
00:05:35,760 --> 00:05:38,560
Speaker 4: opportunity to bring this out in a way where I

100
00:05:38,560 --> 00:05:42,919
Speaker 4: can access both commercial dollars and the funding that is

101
00:05:42,960 --> 00:05:44,520
Speaker 4: available for advancing science.

102
00:05:45,680 --> 00:05:45,960
Speaker 1: Yeah.

103
00:05:46,000 --> 00:05:50,760
Speaker 3: I also think about, you know, how patient Jenny investors

104
00:05:50,760 --> 00:05:53,320
Speaker 3: have to be for really seeing the AI payoff when

105
00:05:53,360 --> 00:05:56,000
Speaker 3: it comes to you know, either biotech developments. We know

106
00:05:56,080 --> 00:05:58,919
Speaker 3: some of this stuff takes time in a normal world,

107
00:05:59,240 --> 00:06:02,080
Speaker 3: and we know AI I can certainly speed up things.

108
00:06:02,080 --> 00:06:06,400
Speaker 3: But I'm just curious, does the time frame for figuring

109
00:06:06,400 --> 00:06:11,000
Speaker 3: out developments in this area is it sped up because

110
00:06:11,040 --> 00:06:12,880
Speaker 3: of AI or is it still going to take a while.

111
00:06:14,360 --> 00:06:17,080
Speaker 4: This is such an important point, Carol. We have to

112
00:06:17,160 --> 00:06:20,480
Speaker 4: keep in mind that many of the accelerations that we're

113
00:06:20,520 --> 00:06:23,560
Speaker 4: talking about that AI can bring to the practice of

114
00:06:23,640 --> 00:06:27,920
Speaker 4: science is still happening at the beginning of a journey too.

115
00:06:28,080 --> 00:06:32,480
Speaker 4: For example, bring a new intervention or diagnostic product to market,

116
00:06:32,880 --> 00:06:36,320
Speaker 4: and so perhaps it can help us come up with

117
00:06:37,080 --> 00:06:42,960
Speaker 4: novel medicines or novel targets for medicines, but we're still

118
00:06:43,520 --> 00:06:47,720
Speaker 4: looking at the beginning of the multi year, many hundreds

119
00:06:47,760 --> 00:06:52,520
Speaker 4: of millions of dollars journey to bring a drug properly

120
00:06:52,600 --> 00:06:55,440
Speaker 4: through clinical development. So I think it is important to

121
00:06:55,480 --> 00:06:59,320
Speaker 4: your point to temper our excitement about that potential impact

122
00:06:59,360 --> 00:07:02,359
Speaker 4: with the overlay of the timelines that it takes to

123
00:07:02,520 --> 00:07:06,799
Speaker 4: actually properly investigate and develop and launch medicines.

124
00:07:08,600 --> 00:07:11,200
Speaker 3: Very cool stuff I was thinking about too. We had

125
00:07:11,720 --> 00:07:16,560
Speaker 3: a conversation with Kathy Wood and talking about AI certainly

126
00:07:16,880 --> 00:07:20,680
Speaker 3: in healthcare and drug developments as well. Yeah, definitely bullish.

127
00:07:20,720 --> 00:07:24,040
Speaker 3: So we highly recommend folks check out that conversation, but

128
00:07:24,120 --> 00:07:27,560
Speaker 3: Jenny always loved touching base with you. Certainly an important

129
00:07:27,640 --> 00:07:29,600
Speaker 3: area to have on our radar, and that of course

130
00:07:29,720 --> 00:07:32,400
Speaker 3: was Jenny Rook, founder managing director of Generadventures. Good to

131
00:07:32,640 --> 00:07:34,600
Speaker 3: check in with her, joining us from the West Coast,

132
00:07:34,640 --> 00:07:35,280
Speaker 3: San Francisco,